ONXEO (EPA:ALONX) | WebDisclosure

Basculer en Français

9479	Companies
185511	Keywords
117901	Articles
99365	Press releases

Home
Companies
ONXEO

BRIEF

published on 06/05/2024 at 07:05, 1 year 6 months ago

Minutes of the general meeting of Valerio Therapeutics

Biotechnology Voting Results General Meeting Resolutions Valerio Therapeutics
PRESS RELEASE

published on 06/05/2024 at 07:00, 1 year 6 months ago

Inside Information / Other news releases
Valerio Therapeutics reports successful Combined General Meeting with 48.1% quorum, adopting all resolutions. Consolidated vote results and meeting minutes to be available on the Company's website

Euronext Growth Paris Biotechnology General Meeting Valerio Therapeutics DDR Drugs
PRESS RELEASE

published on 06/05/2024 at 07:00, 1 year 6 months ago

Informations privilégiées / Autres communiqués
Valerio Therapeutics a tenu son assemblée générale mixte avec succès, adoptant toutes les résolutions du Conseil d'Administration. La Société se spécialise dans le développement de médicaments innovants ciblant les mécanismes de réponse aux dommages de l’ADN tumoral et les oncogènes pilotes

Biotechnologie Assemblée Générale Cancer Valerio Therapeutics ADN Tumoral
BRIEF

published on 05/22/2024 at 20:51, 1 year 6 months ago

Valerio Therapeutics fait progresser l'essai clinique VIO-01 avec des résultats positifs

Essai Clinique Développement De Médicaments VIO-01 Valerio Thérapeutique Tumeurs Solides
BRIEF

published on 05/22/2024 at 20:51, 1 year 6 months ago

Valerio Therapeutics Advances VIO-01 Clinical Trial with Positive Results

Drug Development Solid Tumors Clinical Trial Valerio Therapeutics VIO-01
PRESS RELEASE

published on 05/22/2024 at 20:46, 1 year 6 months ago

Informations privilégiées / Autres communiqués
Valerio Therapeutics annonce l'achèvement du dosage de la première cohorte de sujets dans son essai clinique de phase 1/2 VIO-01 pour traiter les tumeurs solides sans événements indésirables graves rapportés

Biotechnologie Essai Clinique Valerio Therapeutics VIO-01 Tumeurs Solides
PRESS RELEASE

published on 05/22/2024 at 20:46, 1 year 6 months ago

Inside Information / Other news releases
Valerio Therapeutics completes dosing for first cohort of subjects in Phase 1/2 VIO-01 trial for solid tumors, showing encouraging tolerability. Phase 1b aims to determine recommended dose in selected solid tumors

Solid Tumors Valerio Therapeutics VIO-01 Trial Phase 1/2 DNA Damage Response
BRIEF

published on 04/30/2024 at 23:19, 1 year 7 months ago

Valerio Therapeutics Reports 2023 Fiscal Year Results and Clinical Updates

Biotechnology Clinical Trials Financial Results 2023 Valerio Therapeutics VIO-01
BRIEF

published on 04/30/2024 at 23:19, 1 year 7 months ago

Valerio Therapeutics publie ses résultats pour l'exercice 2023 et des mises à jour cliniques

Biotechnologie Résultats Financiers 2023 Essais Cliniques VIO-01 Valerio Thérapeutique
PRESS RELEASE

published on 04/30/2024 at 23:14, 1 year 7 months ago

Rapports financiers et d'audit annuels / Modalités de mise à disposition du rapport financier annuel
Valerio Therapeutics publie ses résultats financiers 2023 et les avancées de son développement clinique. Une trésorerie de 6,8 millions d'euros au 31 décembre 2023 assure la visibilité financière jusqu'à fin 2024

Résultats Financiers Biotechnologie Trésorerie Développement Clinique Valerio Therapeutics

Accesswire

Published on 12/05/2025 at 18:00, 11 minutes ago

SMX: A New Supply Chain Reality in the World's Four Largest Markets
Published on 12/05/2025 at 17:15, 56 minutes ago

TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 17:00, 1 hour 11 minutes ago

Three Trillion-Dollar Frontiers, One Technology: How SMX Is Everywhere at Once
Published on 12/05/2025 at 16:00, 2 hours 11 minutes ago

SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 2 hours 26 minutes ago

Critical Elements announce la clôture d'un placement privé de 7,0 $ million ca par voie de prise ferme

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 17:51, 19 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 25 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:00, 1 hour 11 minutes ago

EQS-Adhoc: The NAGA Group AG adjusts guidance for financial year 2025 following continued low volatility and weaker year-end performance
Published on 12/05/2025 at 16:25, 1 hour 46 minutes ago

4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 2 hours 1 minute ago

Reorganization of the Eckert & Ziegler Executive Board

Les Echos

Published on 12/05/2025 at 17:18, 53 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 53 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 3 hours ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 3 hours ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 4 hours 12 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE